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Objectives: The purpose of this study was to investigate in-vivo visible imaging of oral 
squamous cell carcinoma (OSCC) by targeting epidermal growth factor receptor (EGFR) with 
near-infrared quantum dots.
Materials and methods: Quantum dots with an emission wavelength of 800 nm (QD800) 
were conjugated to monoclonal antibodies against EGFR, resulting in the probe designated as 
QD800-EGFR Ab. OSCC cell line (BcaCD885) expressing high levels of EGFR was transplanted 
subcutaneously into nude mice cheeks to develop an OSCC animal model. QD800-EGFR Ab 
containing 100 pmol equivalent of QD800 was intravenously injected into the animal model, 
and in-situ and in-vivo imaging of cheek squamous cell carcinoma was analyzed at 10 differ-
ent time points.
Results and conclusion: In-vivo imaging and immunohistochemical examination of the 
tumors showed that intravenously injected QD800-EGFR Ab probe could bind EGFR expressed 
on BcaCD885 cells. Fluorescence signals of BcaCD885 cells labeled with QD800-EGFR Ab 
probe could be clearly detected, and these fluorescence signals lasted for 24 hours. The most 
complete tumor images with maximal signal-to-noise ratio were observed from 15 minutes to 
6 hours after injection of the probe. To the best of the authors’ knowledge, this is the first study 
that has obtained clear in-situ and in-vivo imaging of head and neck cancer by using QD800-
EGFR Ab probe. The authors conclude that the combination of near-infrared quantum dots that 
are highly penetrating for tissues with EGFR monoclonal antibody has promising prospects in 
in-vivo imaging of OSCC and development of personalized surgical therapies.
Keywords: oral cancer, head and neck cancer, near-infrared fluorescence, visual in-vivo 
  imaging, epidermal growth factor receptor, nanotechnology
Introduction
Oral squamous cell carcinoma (OSCC) accounts for 90% of oral cancer, and currently 
surgery is one of the main treatments.1 The most difficult part in surgery is to correctly 
define the boundary of the tumor and precisely determine the regions for surgical 
resection in order to improve survival rate and quality of life. Visualized methods 
to detect the tumor cells during surgery are currently not available. Clinical doctors 
estimate the tumor boundary for surgical resection by experience and the changes of 
the tumor tissue texture, which results in a 40% failure rate of complete removal of 
head and neck cancer2,3 and greatly affects the survival rate of the patients. Therefore, 
development of methods for real-time identification of tumor cells during surgery 
and establishment of tailored surgical resection for each individual are one of the key 
factors in improving survival rate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Recently, quantum dots (QDs) were developed on the 
interdisciplinary advancement of nanotechnology, chemistry, 
and optics. The unique optical properties of QDs have shown 
promising prospects in the personalized surgical treatment for 
cancer patients.4,5 QDs are nanocrystals (with a diameter of 
2–10°nm) composed of elements belonging to group II-IV or 
group III-V . Compared with traditional fluorescence markers, 
QDs have narrow emission spectrum, wide excitation spec-
trum, high intensity of fluorescence, and good photochemical 
stability due to the quantum size and dielectric confinement 
effects. In addition, any emission spectrum from ultraviolet to 
near-infrared (or from blue to red) under the same excitation 
wavelength of light can be obtained by changing the particle 
size of QDs.6–8 These optical characteristics of QDs are not 
possessed by any of the current fluorescent probes, including 
a variety of organic fluorescent dyes and fluorescent proteins. 
Particularly, the fluorescence of recently developed QDs 
with an emission of near-infrared wavelength from 700 nm 
to 900 nm has strong penetration in human tissues, which is 
extremely suitable for visible in-vivo medical imaging.9–11 
Currently, fluorescent probes have been developed by 
conjugating QDs with target molecules (eg, antibodies and 
peptides) and have been used for in-vivo visualization of can-
cer cells and tumor angiogenesis,4,12–14 sentinel lymph node 
detection,15,16 and imaging of drug targeting studies.17 These 
studies have demonstrated that excellent optical properties 
of QDs have promising prospects in visualization of cancer 
development and personalized therapies. Because QDs are 
made of toxic heavy metal materials, previous studies have 
shown that toxicity of the QDs mainly comes from a quick 
release of heavy metal (such as Cd). In contrast, current 
biologically functionalized QDs have excellent biological 
compatibility and water solubility. More importantly, these 
biologically functionalized QDs do not have obvious side 
effects in humans at the required range of detection dosage 
and do not affect the growth, differentiation, and function 
of cells.7,8,18–20
Many studies have demonstrated that 90% of OSCCs 
and head and neck squamous cell carcinomas (HNSCCs) 
highly express epidermal growth factor receptor (EGFR).21,22 
Specific targeting of EGFR by EGFR antibodies has been 
widely used for the treatment of OSCC and HNSCC.22,23 
Therefore, visual imaging by targeting EGFR has broad 
applicability for OSCC and HNSCC. Visualization of in-
situ and in-vivo imaging for OSCC and HNSCC by EGFR 
antibody conjugated QDs has not been reported. The authors 
of this paper attached EGFR monoclonal antibodies to QDs 
with a maximal emission wavelength of 800 nm to produce 
a probe designated as QD800-EGFR Ab. OSCC animal 
model was developed by transplanting nude mice subcutane-
ously with human buccal squamous cell carcinoma cell line 
(BcaCD885). Finally, QD800-EGFR Ab was intravenously 
injected into the animal model for in-situ and in-vivo imag-
ing of OSCC. The results obtained in this study provided 
fundamental bases for personalized surgical treatment of 
OSCC and HNSCC by using QDs.
Materials and methods
Main equipment and reagents
BcaCD885 was provided by West China College of Stoma-
tology, Sichuan University (China). Qdot®800 Antibody 
Conjugation Kits were purchased from Invitrogen (Carlsbad, 
CA). A recombinant human/mouse chimeric anti-EGFR 
monoclonal antibody and HistostainTM-Plus kits were pur-
chased from Beijing Zhong Shan Company (China). A laser 
scanning confocal microscope (TCS-SP5) was purchased 
from Leica (Germany). The Maestro In-Vivo imaging system 
was purchased from CRi Inc (Woburn, MA).
experimental animals
Specific-pathogen-free level BALB/c (strain nu/nu) nude 
mice (n = 18, female, 6–8 weeks old, weight 20–25 g) 
were purchased from the Experimental Animal Center of 
Chongqing Medical University. The mice were bred in 
constant temperature and humidity conditions. Feeds, beds, 
and drinking water were sterilized. All the experimental 
procedures were approved by the Animal Administration 
Committee of the Institute of Chongqing University.
Preparation and purification  
of qD800-egFr Ab probe
Preparation of QD800-EGFR Ab probes was performed 
according to instructions of the Qdot Antibody Conjugation 
Kits. Briefly, 14 µL of the dual function SMCC (succinimidyl-
4-(N-maleimidomethyl)cyclohexane-1-carboxylate) solution 
(10 mM) was mixed with 125 µL of QD800 solution (4 µM) 
for 1 hour at room temperature. After 1-hour activation, 
the mixture was loaded onto an NAPTM-5 (GE Healthcare, 
Little Chalfont, UK) column and a total of 500 µL elution 
(Elution 1) was collected. A total of 6.1 µL of dithiothreitol 
solution (1 M) was added to 300 µL of EGFR monoclonal 
antibody (1 mg/mL). After 30 minutes of reduction reaction 
at room temperature, the dye indicators were added. The 
mixture was loaded onto an NAP-5 column, and a total of 
500 µL   elution (Elution 2) was collected. Elution 1 and 
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  temperature, 3 µL of 2-mercaptoethanol (10 mM) was added 
for 30 minutes of inactivation. The coupled and inactivated 
solution obtained above was added into an ultra-filtration 
tube and was centrifuged for 15 minutes at 7000 rpm. The 
solution in the inner membrane of the ultra-filtration tube 
was collected and chromatography was conducted to obtain 
purified QD800-EGFR Ab probe. Finally, the concentration 
of QD800-EGFR Ab was calculated using the following for-
mula: A = εcl, where A represented absorbance, ε represented 
the extinction coefficient, c represented the concentration, 
and l represented the optical path.
Immunohistochemical detection of egFr
One milliliter of BcaCD885 cells at a concentration of 
2 × 104 cells/mL were seeded into each well of a 24-well 
plate containing a glass coverslip. After 24 hours of cul-
ture, the glass coverslip was taken out and fixed with 4% 
paraformaldehyde for 30 minutes. Streptavidin peroxidase 
(SP) immunohistochemical staining was performed accord-
ing to instructions of the Histostain-Plus kits. Briefly, the 
coverslips were incubated with 3% H2O2 deionized water 
for 10 minutes, washed with distilled water, and soaked in 
phosphate buffered saline (PBS) for 5 minutes. Consequently, 
the coverslips were incubated with normal goat serum at 
room temperature for 15 minutes before EGFR monoclonal 
antibody (1:100) was added. After incubation overnight at 
4°C, the coverslips were washed with PBS three times and 
then biotin-labeled goat anti-rabbit immunoglobulin G and 
streptavidin conjugate of horseradish peroxidase were added. 
Finally, diaminobenzidine was added for color development. 
Negative control was performed by replacing the primary 
antibody with PBS. Positive control was provided by the 
Histostain-Plus kits. Appearance of brown-yellow granules   
within the cells indicated positive.
In-vitro detection of the binding between 
egFr and qD800-egFr Ab probe
BcaCD885 cells at a concentration of 5 × 104 cells/mL were 
seeded onto three 35 mm-culture dishes with glass bottoms 
(1 mL in each dish). After 24 hours of culture, the cells were 
washed twice with PBS, and the cells were divided into three 
groups. The experimental group was added with 100 µL 
of QD800-EGFR Ab probe (100 nM). The control group 
I was added to 100 µL of QD800 (100 nM). The control 
group II was added to 200 µL of EGFR monoclonal antibody 
(1 µg/mL) for 2 hours of blocking. Subsequently, the cells 
were washed twice with PBS and then an equimolar amount 
of QD800-EGFR Ab probe was added to the experimental 
group. The cells in the three groups described above were 
incubated for 30 minutes at 37°C and then washed with PBS 
three times. Distribution of QD800 fluorescence within the 
cells was analyzed by confocal microscopy. All the experi-
ments were repeated three times.
In-vivo imaging of BcaCD885 cells  
by QD800-EGFR Ab probe in the  
OSCC mice models
BcaCD885 cell suspension (1 × 106) in 0.1 mL PBS was 
transplanted subcutaneously into the right cheek of the nude 
mice (n = 18) to develop the BcaCD885 cheek squamous cell 
carcinoma model. Three weeks post-injection, the maximal 
diameter of the tumor reached 0.8–1.1 cm. The mice were 
divided into the experimental group (n = 6), control group I 
(n = 6), and control group II (n = 6). All the animals were 
anaesthetized by intraperitoneal injection of 2% pentobar-
bital (40 mg/kg). Subsequently, for the experimental group, 
100 µL of QD800-EGFR Ab probe containing 100 pmol 
equivalent of QD800 was injected into the mice through the 
tail vein. For control group I, 100 µL of QD800 (100 pmol) 
was injected. For control group II, 250 µL of EGFR mono-
clonal antibody (1 mg/mL) was injected and 24 hours later 
an equimolar amount of QD800-EGFR Ab probe was 
injected. In-vivo imaging detection was performed 15 and 
30 minutes, and 1, 2, 3, 4, 6, 8, 10, and 24 hours post-injection 
of QD800-EGFR Ab probe and QD800 using the Maestro 
in-vivo imaging system. Images were analyzed by Maestro 
2.10.0 software.
cellular and histological examination  
of the BcacD885 tumors
Two mice from the experimental group, control group I, 
and control group II were euthanized 3 hours after injection 
of QD800-EGFR Ab probe and QD800. The remaining 
four mice from the experimental and control groups were 
euthanized 24 hours after QD800-EGFR Ab probe injection. 
The subcutaneous cheek tumors were removed from the 
euthanized mice and embedded in optimal cutting tempera-
ture compound. The embedded samples were frozen, and 
cryo-sections with a thickness of 7 µm were continuously 
cut under −20°C conditions. One of every two continuous 
sections was conducted with hematoxylin and eosin (H&E) 
staining for observation of the tumor growth. The nucleus 
in another section was stained blue with Hoechst 33342 
(0.5 µg/mL) for 5 minutes and then washed with PBS three 
times. Distribution of QD800 fluorescence in the tumor 
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statistical analysis
The values were expressed as the mean ± standard error. 
Statistical analysis was performed using Student’s t-test. 
A P-value , 0.05 was considered to be statistically   significant. 
All statistical analyses were performed using the SPSS Statis-
tics (IBM Corporation, Somers, NY) software package.
Results
Preparation and purification  
of qD800-egFr Ab probe
Based on the extinction coefficient of QD800 at 550 nm 
(ε550 = 1.7 × 106 (mol/L)–1 cm–1), the concentration of the puri-
fied QD800-EGFR Ab probe was calculated to be 2 µM.
QD800-EGFR Ab probe specifically binds 
egFr of BcacD885 cells in vitro
SP immunohistochemical analysis indicated that EGFR 
was expressed on the membrane and in the cytoplasm of 
BcaCD855 cells (Figure 1). Direct immunofluorescence 
examination with QD800-EGFR Ab probe showed that red 
fluorescence was present on the membrane of BcaCD885 cells 
in the experimental group. In contrast, red fluorescence was 
not observed in the BcaCD885 cells in control groups I or II 
(Figure 2). These results demonstrated that QD800-EGFR 
Ab probe cannot label EGFR of BcaCD885 cells that had 
been blocked by EGFR antibody. In contrast, QD800-EGFR 
Ab probe can recognize and bind efficiently with unblocked 
EGFR of BcaCD885 cells in vitro.
Visible in-situ and in-vivo imaging  
of Oscc by qD800-egFr Ab probe
In-vivo imaging analysis showed that the size of the 
  fluorescence signal equivalent to the size of the tumors can 
be detected 15 minutes after injection of QD800-EGFR Ab 
probe in the experimental group. The size of fluorescent 
signal persisted for 6 hours post-injection, and after 8 hours 
the size of the signal began to become significantly smaller 
(Figure 3A). Twenty-four hours after the probe injection, 
the fluorescent signal was very weak (Figure 3A). The 
signal-to-noise ratio (the fluorescence intensity ratio between 
tumor and background) was high from 15 minutes to 6 hours 
post-injection. This signal-to-noise ratio began to decrease 
significantly after 8 hours and was close to the baseline level 
after 24 hours (Figure 3C). In control group I, QD800 was 
not conjugated with EGFR Ab. In control group II, EGFR 
was blocked before injection of QD800-EGFR Ab probe, 
and thus only a very weak fluorescence signal was detected 
on the tumor sites 15 minutes post-injection in control 
groups I and II. This weak signal could be due to the nonspe-
cific phagocytosis of QD800-EGFR Ab probe and QD800 by 
BcaCD885 cells. However, the fluorescence signal above the 
background level was never detected 30 minutes to 24 hours 
post-injection in control groups I and II (Figure 3B).
cellular and histological detection  
of BcacD885 tumors
H&E staining of the tumor sections from the mice 3 and 
24 hours post-injection showed a large amount of tumor cells, 
and the tumors grew well (Figure 4). The nucleus of tumor 
Experimental Control group
200 µm 200 µm
Figure 1 Immunohistochemical examination of egFr expression on the membrane 
and in the cytoplasm of BcacD885 cells in the experimental group and control 
group (the primary antibody was replaced by PBs) (sP × 200).
Abbreviations: BcacD885, human buccal squamous cell carcinoma cell line; egFr, 
epidermal growth factor receptor; PBs, phosphate buffered saline; sP, streptavidin 
peroxidase.
Bright-field QD800 fluorescence image Overlay image
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B
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Figure  2  In-vitro  labeling  of  BcacD885  cells  with  qD800-egFr  Ab  probe. 
Detection of the fluorescence was conducted after 30 minutes of labeling. The 
excitation wavelength was 405 nm, and the emission wavelength was 750–800 nm. 
(A)  experimental  group:  the  cells  were  labeled  with  qD800-egFr  Ab  probe 
(100 nM) at 37°c for 30 minutes. (B) control group I: the cells were added with 
qD800 (100 nM) at 37°c for 30 minutes. (C) control group II: the cells were 
blocked with 200 µL of egFr monoclonal antibody (1 µg/mL) for 2 hours before 
addition of qD800-egFr Ab probe (100 nM) at 37°c for 30 minutes.
Abbreviations: Ab, antibodies; BcacD885, human buccal squamous cell carcinoma 
cell line; egFr, epidermal growth factor receptor; qD800, quantum dots with a 
maximal emission wavelength of 800 nm.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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sections was stained blue by Hoechst 33342 under confocal 
microscope. QD800 fluorescence signal was not detected 
in the tumor section of the mice in control groups I and II 
3 and 24 hours post-injection. In contrast, in the experimental 
group, QD800 fluorescence signal was detected outside of 
most of the nucleus in the tumor section of the mice 3 hours 
post-injection (Figure 5). Twenty-four hours post-injection, a 
fluorescence signal was detected only outside a small number 
of nuclei (Figure 5). The fluorescence signal was distributed 
in the cytoplasm and on the membrane. These results indi-
cated that QD800-EGFR Ab probe can specifically target 
and bind EGFR of BcaCD885 cells.
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Figure 3 Visible imaging of BcacD885 cells in the cheek squamous cell carcinoma animal model by qD800-egFr Ab probe at different times (excitation/emission 
630/800 nm; exposure time 50 ms; collection time 10 seconds, 2 × 2 Binning 1024 × 1024 pixels). (A) Visible images of BcacD885 cheek squamous cell carcinoma mice after 
intravenous injection with qD800-egFr Ab probe containing 100 pmol equivalent of qD800 in the experimental group. (B) Visible images of BcacD885 cheek squamous 
cell carcinoma mice after intravenous injection with 100 pmol qD800 in control group I. (C) Visible images of BcacD885 cheek squamous cell carcinoma mice in control 
group II (250 µL of egFr monoclonal antibody (1 mg/mL) was injected, and 24 hours later qD800-egFr Ab probe containing 100 pmol equivalent of qD800 was injected). 
(D) The signal-to-noise ratio in the BcacD885 squamous cell carcinoma model after different times of probe injection in the experimental group.
Abbreviations: Ab, antibodies; BcacD885, human buccal squamous cell carcinoma cell line; egFr, epidermal growth factor receptor; qD800, quantum dots with a maximal 
emission wavelength of 800 nm.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Discussion
Development of methods to visualize tumor cells during 
surgery and determine the precise boundary of the tumors 
for personalized surgical resection is the key to improve the 
survival rate of cancer patients. Traditional methods (eg, 
computed tomography [CT] and magnetic resonance imaging 
[MRI]) that can provide good imaging detection of tumors are 
not suitable for visible detection of tumor cells during surgery. 
Optical examination is clinically the safest, simplest, and 
most economical method. QDs have unique optical properties 
as mentioned earlier. More importantly, QDs can be easily 
modified and conjugated by other biological molecules. As 
nanoparticles, QDs with good photochemical stability can 
easily penetrate tumor angiogenesis and access cancer cells. 
Therefore, QDs have shown unique advantages in the surgical 
treatment of individual cancer patients.6–11
In this study, we intravenously injected QD800-EGFR Ab 
probe to target EGFR, which is highly expressed by OSCC. 
In-vivo imaging and tumor immunohistochemical analysis 
showed that QD800-EGFR Ab probe can specifically bind 
BcaCD885 cells with high level expression of EGFR. Thus, 
the fluorescence of QD800 can represent the presence of 
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Figure 4 h&e staining of tumor section from the experimental group (intravenous 
injection of qD800-egFr Ab probe), control group I (intravenous injection of 
qD800), and control group II (preinjection of egFr monoclonal antibody 24 hours 
before qD800-egFr Ab probe injection) of BcacD885 squamous cell carcinoma 3 
and 24 hours after probe injection (×200).
Abbreviations: Ab, antibodies; BcacD885, human buccal squamous cell carcinoma 
cell line; egFr, epidermal growth factor receptor; h&e, hematoxylin and eosin; 
qD800, quantum dots with a maximal emission wavelength of 800 nm.
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Figure 5 Laser scanning confocal microscope analysis of tumor section from the 
experimental  group  (intravenous  injection  of  qD800-egFr  Ab  probe),  control 
group I (intravenous injection of qD800), and control group II (preinjection of 
egFr monoclonal antibody 24 hours before qD800-egFr Ab probe injection) of 
BcacD885 squamous cell carcinoma 3 and 24 hours after probe injection. Nucleus 
was stained by hoechst 33342.
Abbreviations: Ab, antibodies; BcacD885, human buccal squamous cell carcinoma 
cell line; egFr, epidermal growth factor receptor; qD800, quantum dots with a 
maximal emission wavelength of 800 nm.
BcaCD885 cells and can be visualized from outside of the 
body; toxicity of the QDs in the mice was not observed in 
this study. The complex metabolic process of QD800-EGFR 
Ab probe in the body is currently unknown. However, we 
obtained the most complete fluorescence images and highest 
signal-to-noise ratio 15 minutes to 6 hours post-injection, 
indicating that the optimal time period for personalized 
surgery is between 15 minutes and 6 hours after injection of 
QD800-EGFR Ab probe. Previous studies4,10 also show that 
104 cancer cells can be visibly detected after QD800 labeling 
in the presence of skin barrier. This sensitivity was 100-fold 
higher than that of CT and MRI. In addition, the sensitivity 
can be further enhanced when the tumor is exposed during 
the surgery. Gao et al predicted that in-vivo visible   imaging International Journal of Nanomedicine
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can detect as low as 10–100 QD-labeled cancer cells.24 With 
the continuous advancement in imaging techniques, and 
synthesis of QDs with stronger penetration abilities for tis-
sues, the authors of this paper believe that visible imaging 
detection can reach sensitivity at single-cell level under the 
wound exposure condition. In the future, clinical doctors will 
only need to wear a very small excitation source and near-
infrared light receiver to perform personalized and tailored 
surgical removal of real tumors.
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